Today, in vivo allergy diagnosis and allergen-specific immunotherapy (AIT) are still based on allergen extracts obtained from natural allergen sources. Several studies analyzing the composition of natural allergen extracts have shown severe problems regarding their quality such as the presence of undefined nonallergenic materials, contaminants as well as high variabilities regarding contents and biological activity of individual allergens. Despite the increasing availability of sophisticated analytical technologies, these problems cannot be overcome because they are inherent to allergen sources and methods of extract production. For in vitro allergy diagnosis problems related to natural allergen extracts have been largely overcome by the implementation of recombinant allergen molecules that are defined regarding purity and biological activity. However, no such advances have been made for allergen preparations to be used in vivo for diagnosis and therapy. No clinical studies have been performed for allergen extracts available for in vivo allergy diagnosis that document safety, sensitivity, and specificity of the products. Only for very few 
therapeutic allergen extracts state-of-the-art clinical studies have been performed that provide evidence for safety and efficacy. In this article, we discuss problems related to the inconsistent quality of products based on natural allergen extracts and share our observations that most of the products available for in vivo diagnosis and AIT do not meet the international standards for medicinal products. We argue that a replacement of natural allergen extracts by defined recombinantly produced allergen molecules and/or mixtures thereof may be the only way to guarantee the supply of clinicians with state-of-the-art medicinal products for in vivo diagnosis and treatment of allergic patients in the future.
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Allergy; Allergen; Diagnosis; Allergen-specific immunotherapy; Allergen extract; Quality control; Recombinant allergen; Molecular allergy diagnosis IgE-associated allergy is the most common and important immunologically mediated hypersensitivity disease affecting approximately 30% of the population worldwide.1,2 In the USA, allergies are a leading cause of chronic illness representing an immense burden for the health care system. 3 The identification of the disease-causing allergens is critical for the accurate diagnosis of allergy and forms the basis for the treatment of allergic patients by allergen-specific interventions (eg, allergen avoidance, diet, allergen-specific immunotherapy [AIT] ). 4 AIT is in fact the only causal, disease-modifying, and long-lasting form of treatment.4,5 Therefore considerable efforts have been spent in the characterization of allergens beginning with the isolation of allergens from the natural allergen sources by biochemical means.2,6,7 A major breakthrough regarding allergen characterization has been achieved with the introduction of molecular cloning techniques for the isolation of the genes coding for allergens.8 Thirty years ago the genes coding for the first allergens were isolated and sequenced, and soon thereafter the first recombinant allergens were produced and used for in vitro diagnosis of allergy.9-11 In 1999, recombinant allergens were made available in a fully automated in vitro allergy diagnostic test system,12 and the first allergen chip containing micro-arrayed allergen molecules to be used as a multiallergen test was reported in 2002. 13 Since then, in vitro allergy diagnosis has been revolutionized by molecular allergy diagnosis.6,14 However, recombinant allergen molecules have also been used for in vivo allergy diagnosis. More than 20 years ago the first skin prick test studies and also in vivo provocation test studies (eg, bronchial provocation, nasal provocation) were performed Likewise, recombinant allergen derivatives and recombinant allergens have been successfully evaluated for AIT more than 10 years ago.24-26 Unfortunately, only few molecular AIT approaches have been moved successfully into clinical evaluation,24-31 and there are therefore currently only allergen extract-based allergy vaccines available.
However, also only for few of the allergen extract-based AITs safety and efficacy have been documented according to the current rules for medicinal products as demanded by the European Directive 2001/83/EC in 2004.32 For most of the AIT products, no sufficient documentation in the form of properly randomized, double-blind, placebo-controlled clinical trials is available. We found only 2 subcutaneous immunotherapy (SCIT) products for grass pollen allergy,33,34 2 sublingual immunotherapy (SLIT) products for grass pollen allergy, 35-37 1 SLIT product for ragweed pollen allergy,38 and 2 SLIT products for house dust mite allergy,39-43 which have been evaluated in large numbers of patients. Several largescale clinical trials with allergen extracts are currently registered in the clinical trial database (https://clinicaltrials.gov/), but results are not yet published and it seems that a longer transition period is needed to implement European Directive 2001/83/EC. Regarding allergen extracts for in vivo diagnostic testing so far no studies and/or documentation satisfying the demands of European Directive 2001/83/EC are available and there are discussions ongoing if there should be a distinction between therapeutic and diagnostic allergen preparations.
In the next section, we discuss the problems that are associated with the preparation and characterization of allergen extracts from natural allergen sources to meet current requirements for medicinal products. Although allergen extracts to be used for in vivo allergy diagnosis and AIT need to be distinguished, they fall under the definition of medicinal products (ie, "any substance or combination of substances that may be used in or administered to human beings either with a view to restoring, correcting, or modifying physiological functions by exerting a pharmacological, immunological, or metabolic action, or to making a medical diagnosis").
Allergen Extracts: Production and Quality Control
For a long time expert opinion was sufficient to place allergen products for in vivo diagnosis and therapy on the market and clinical studies following good clinical practice (GCP) standards were never performed. In many countries, especially in the European Union, the legal situation has dramatically changed during the last 2 decades. It is now required to demonstrate safety and efficacy for therapeutic allergen products as well as for allergen products used for in vivo application such as diagnostic allergen extracts used for provocation testing, including skin testing, bronchial, nasal, conjunctival, and food provocation testing.44,45 Although there are differences regarding the regulations in different continents and countries,44-49 the overall goal is that according to the "International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use" (http://www.ich.org/home.html), medicinal products that include also allergen products for in vivo diagnosis and treatment must be evaluated in clinical trials and undergo a thorough evaluation to be registered for use in patients. A major prerequisite for clinical trials and subsequent use in humans is that the medicinal product is produced following good manufacturing practice (GMP) and is shown to have consistent characteristics and quality. This requirement is already a major hurdle for allergen extracts that are produced from natural allergen sources. Figure 1 provides an overview of the steps leading to a diagnostic or therapeutic allergen extract. A first major problem relies in the allergen source that is used for the production of allergen extracts. The contents, concentrations, and ratios of the individual allergens have been reported to vary greatly depending on a large variety of factors.50-55 Only a few examples shall be mentioned in this context: for example, allergen contents in pollen vary depending on environmental factors such as ozone exposure,56 pollution,57 and plant species to name a few. 58 The contents of house dust mite allergens and their ratios depend on the growth conditions of mites, how they are fed and cultivated, and what mite material (feces, bodies) is used as raw material for the production of extracts.59 In the case of animal allergens, allergen type and contents may vary depending on gender.60,61 Food allergens are expressed to a different extent in different parts of fruits and cultivars,62 and are extracted differently depending on the method used for extraction.63 Lipophilic allergens have therefore been overlooked for a long time. 64, 65 The spectrum of mold allergens shows great variation depending on mold strains and culture conditions.55 Furthermore, it has been shown that allergens occur in pollen as different isoforms with different allergenic activities and immunological properties in varying quantities, which means that no homogeneous single natural allergen preparation can be obtained from a natural allergen source.66-68 Therefore, only the recombinant expression of a defined isoform based on the corresponding gene can overcome this problem.
The presence of proteases in allergen extracts is another major problem because it may lead to the degradation of allergens that affects the allergenic activity, immunogenicity, and immunomodulatory capacity of an allergen extract.69-74 Because protease inhibitors that can help overcoming this problem are often toxic, it is impossible to prevent allergen degradation in extracts by the addition of such protease inhibitors. Certain allergens are proteases by themselves and therefore can digest not only other allergens but also may have effects on immune cells and tissues in the allergic patient on administration. This was shown for example for fungal allergens in mouse models but also for the major house dust mite allergen ex vivo for the human system. [71] [72] [73] [74] Some allergens are toxic and, at high concentrations, may induce inflammatory reactions per se in a nonsensitized subject. 75 Another major problem is that allergen extracts contain a large variety of unknown nonallergenic materials that may have toxic and/or immunomodulatory effects. For example, it has been shown that nonallergenic components such as pollen-derived phytoprostanes may activate cells of the innate immune system (ie, dendritic cells) "unspecifically" and thus indirectly have effects on the adaptive immune response by inducing Th2 responses. Such effects have been observed for pollen and house dust mite allergen extracts.76,77 Another major concern is that allergen extracts may contain contaminants from other allergen sources. For example, the presence of house mite allergens in animal dander allergen extracts has been reported,78 pollen may be contaminated with unrelated pollen or fungi, and recently the presence of IgE-reactive bacterial antigens in house mite allergen extracts has been reported. 79 When allergen extracts are prepared from natural allergen sources, one must therefore analyze not only the presence of intact allergens but also of allergen-derived materials exhibiting different properties as the intact allergens (eg, allergen peptides) (Figure 1 ). In this context, it should be mentioned that fractions of allergen extracts with different molecular weights have been shown to exhibit different allergenic and immunomodulatory properties as has, for example, been shown already early for grass pollen extracts. 80 Furthermore, the presence of nonallergenic materials and possible contaminants requires analysis (Figure 1 ).
The analysis of the different materials in an extract (ie, allergen, allergen-derived materials, nonallergenic materials, contaminants) ( Figure 1 ) must include many different parameters such as contents, concentrations, quality, ratios, activity parameters (eg, allergenic activity, immunogenicity, immunomodulatory activity), shelf-life, and stability; chemical and biological properties related to safety must be characterized for each of the different components, which is an extremely complex process. There are methods that in principle allow us to analyze the aforementioned parameters for single molecules with sufficient accuracy. Mass spectrometry has recently been proposed as a method for the standardization of allergen extracts.81 However, mass spectrometry can only demonstrate the presence of certain allergen-derived peptides in an extract but is not a real quantitative method and cannot tell anything about the allergenic or immunogenic properties of the molecules. 82 Unfortunately, there is therefore no method that can analyze all important characteristics (physicochemical, structural, immunological properties) of the individual components present in complex mixtures such as allergen extracts at the same time.
The allergen extraction process is not a real purification process of certain allergen molecules but leads to a crude bulk allergen extract that can be further used for different purposes (Figure 1 ). Allergen extracts for in vivo diagnostic testing are usually prepared from the bulk allergen extracts by dilution and addition of certain preservatives. In this context, it has been found that certain allergen extracts contain also components that have been added during the manufacturing process. For example, human serum albumin is sometimes added by the manufacturers for stabilization purposes.50,51,54 Mixed allergen extracts are produced by mixing bulk allergen extracts from different allergen sources that may create several problems. For example, mixing of allergens dilutes the concentrations of allergens from each of the extracts that has been used for mixing to an unknown extent or may introduce proteases from other allergen sources leading to degradation.83-86 Denaturation of allergen extracts by various physicochemical procedures is performed for allergen extracts used for AIT to reduce the allergenic activity. There are different processes for denaturation such as aldehyde treatment, boiling, chemical denaturation, and various other treatments, but these procedures cannot be fully controlled and therefore affect to various degrees allergenic, immunogenic, and immunomodulatory properties of allergen extracts.87,88 Importantly, individual allergens cannot be traced any more as intact molecules in chemically modified or denatured allergen extracts, and one therefore can only try to assess the overall allergenic and/or immunogenic activity of a denatured extract, both of which may vary from one production batch to another.49,89
Finally, one has to consider that allergen extracts to be used for AIT are manufactured in different ways. Some allergen extracts are made as aqueous solutions without adjuvants, some are mixed with powders and excipients to form tablets, and some extracts are adsorbed to different adjuvants to which individual allergens may bind with different strength and stability.90-93 All these additional processes may affect individual allergens/immunogens to a different extent and thus introduce another layer of uncertainty in addition to those due to variations caused by allergen sources and methods of extraction, processing, denaturation, and mixing.
Methods for the Quality Control of Allergen Extracts
In Table I we have summarized advantages and disadvantages of different methods that can be used for the quality control of allergen extracts. For example, the determination of the total protein contents has been introduced as one of the first methods for the quality control of allergen extracts.94 It measures protein contents but does not identify specifically allergens and their properties. Methods for measuring the allergenic activity and IgE reactivity of allergen extracts (ie, potency assays) were introduced later as additional methods for quality control.95 These methods depend on reagents derived from patients because allergen extracts are assessed for reactivity with IgE antibodies, in basophil activation tests or by skin testing.95,96 Since allergic patients react with different allergens and have different sensitivities to these allergens, results obtained with potency assays depending on patients materials will vary widely. As a result, allergen preparations that are standardized according to such methods in different countries cannot be compared.48 Potency assays measuring the allergenic activity cannot be used for allergen extracts that have been modified to reduce allergenic activity, except one wants to measure the extent of reduction of allergenic activity in comparison with an unmodified allergen extract.
In addition, a series of biochemical and biophysical methods have been developed. They include, for example, mass spectrometry, circular dichroism, size exclusion that allows the detection of allergen peptides, and the analysis of the fold of proteins and of the aggregation behavior, respectively.97,98 In particular, mass spectrometry has been suggested as a powerful method for the standardization of allergen extracts.81,99,100 Although circular dichroism and gel filtration are very useful and suitable for the analysis of single purified molecules,101 these methods cannot be used for complex allergen mixtures. Sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting allow the qualitative analysis of allergen extracts and may discriminate between intact allergens, aggregation, and degradation products according to molecular weight.102 Quantitative enzyme-linked immunosorbent assays performed with allergen-specific antibody probes permit the determination of the concentrations of intact allergens.103-105 The determination of the ability of an allergen extract to induce the production of allergen-specific IgG antibodies that block patients' IgE binding can be obtained by immunization of animals with the formulated vaccine.106 Because antibodies induced in inbred mouse strains by allergy vaccines recognize other epitopes than those induced in allergic patients, it is recommended to perform immunization experiments in outbred animals such as rabbits. 89 The IgG antibodies obtained in the animals can then be tested for their ability to inhibit allergic patients' IgE binding to the allergens and allergen-induced effector cell activation. In fact, a recent study showing that cat allergy can be treated by passive immunization with recombinant allergenespecific antibodies emphasizes the importance of blocking antibodies for success of treatment and the need to test allergy vaccines for the induction of blocking antibodies in model systems. 107 However, clinical studies in humans and postmarketing assessment will always be required to assess the immunogenic properties of AIT vaccines because there may be differences of immunogenicity in animals and man.
In addition to the assays characterizing allergens, allergen-derived materials, nonallergenic components and contaminants, additional tests are mandatory for safety, stability, toxicity, and sterility assessment. These methods are mandatory for the quality control of medicinal products (Table I) .108,109 Table E1 (available in this article's Online Repository at www.jaci-inpractice.org) contains an overview of allergen extracts that we found to be registered or to be available in different continents and countries and, when available, the corresponding homepages of the regulatory agencies providing the information. As examples, we have analyzed a few countries, that is, the USA, Germany, Russia as well as Taiwan and Japan from Asia. However, already in this small selection of countries the heterogeneity of the regulations in different parts of the world becomes very clear.110 However, one common feature seems to be that allergens, regardless of whether they are used for therapy or as in vivo test allergens, are considered as biological medicinal products and therefore require marketing authorizations that are usually issued for the finished product. In the USA, so-called standardized and also nonstandardized injectable allergen extracts from a variety of manufacturers are available (Table E1 ). However, we were unable to find published state-ofthe-art clinical studies that document the safety, specificity, and efficacy for the majority of these products. Randomized, double-blind, placebo-controlled clinical studies following the rules set for medicinal products have only been performed for few extracts available as tablets for sublingual therapy.35-43 The situation was similar for Germany. On the homepage of the Paul Ehrlich Institute that is responsible for the registration of medicinal products in Germany, extracts from several companies for skin testing and provocation testing are listed, but for none of these test allergen extracts we could find any documentation by clinical studies. For a handful of allergen extracts available for subcutaneous and sublingual AIT,33-43 clinical studies have been performed, whereas for the majority of therapeutic products, no evidence for efficacy and safety in the form of clinical studies could be found. In fact, in the European Union (EU), allergen products such as AIT vaccines and allergen products used for in vivo testing are defined as medicinal products according to Directive 2001/83/EC and are therefore required to obtain a market authorization that can follow different procedures in individual EU countries or via a centralized procedure that is valid for the whole EU. 110 The current state-of-the-art approach for obtaining marketing authorization requires randomized, double-blind, placebocontrolled studies that are performed according to GCP guidelines, but in reality this has been fulfilled only for few AIT vaccines in the EU.33-43 A similar situation was found for Russia, Taiwan, and Japan where a quite limited number of allergen extracts are available (Table E1) . One possibility for making allergen extracts available without fulfilling new rules for allergen products is based on so-called named patient products that can be prescribed by practitioners on an individual patient basis.32 However, it must be clear that the level of evidence for such products is very low (ie, expert opinion) and named patient prescription hence does not follow the current rules for medicinal products.
Allergen Extracts for Diagnosis and Treatment
The legal situation in the USA is that allergen products are regulated as biological medicinal products under the Public Health Service Act and as drug product under the Federal Food, Drug and Cosmetics Act, and require a marketing authorization termed a biologics license application (BLA). The BLA has to demonstrate that the product is manufactured under GMP and is safe, pure, and effective. Thus randomized, double-blind, placebo-controlled studies according to the current GCP regulation are now required for marketing authorization. In the EU, the pharmaceutical industry has been requested to provide the necessary documentation for their products, and accordingly clinical studies are currently performed, however, mainly for AIT products but not for allergen extracts used for in vivo testing. It is therefore not surprising that there is a great risk that many natural allergen extracts will disappear in the EU, especially those for in vivo testing.44 Ultimately, also many AIT extracts may not be available any more in the future. Although the regulatory situation is different in other countries, it cannot be excluded that the pressure on quality control on allergen extracts will increase suddenly also there because the continuously rising costs for health care systems will demand that the safety and efficacy of medicinal products and drugs is documented by extensive clinical studies. It will therefore be necessary to intensify the discussions between major allergy societies and international control agencies to provide reliable, safe, efficient, and cost-effective options for therapy and in vivo diagnosis and eventually to distinguish between therapeutic and diagnostic allergen preparations.
Transition from Allergen Extracts to Molecules: The Only Solution?
If indeed the requirements for quality control and the documentation of safety and efficacy by clinical trials set by regulatory authorities increase for test and treatment allergens, there are basically at least 2 options. One option would be to fulfill the requirements with allergen extractebased technologies, whereas the other option would be to replace allergen extracts by defined recombinant allergen molecules and combinations of the 2 options can be envisaged. In Table II , we have performed a SWOT (Strength, Weakness, Opportunity, and Threat) analysis of the advantages and disadvantages of natural allergen extracts versus recombinant allergen molecules. One may argue that allergen extracts are traditional products that are known to the allergologist for a long time without requiring detailed knowledge regarding the individual allergen molecules. However, in the field of in vitro allergy diagnosis, molecular testing has become an important part of the diagnostic armamentarium of the allergologist, and it is argued that molecular testing will eventually completely replace extract-based testing.6,111,112 Of course, molecular testing requires detailed knowledge of the individual allergen molecules and hence continued medical education to enjoy the many advantages of molecular testing (eg, understanding of cross-reactivities, precise identification of the culprit allergen, resolution of complex cases, refinement of AIT prescription, identification of sensitization to high-or low-risk allergens) over allergen extractebased testing.7 One particular strength of molecular allergy diagnosis is that it allows us to identify precisely the culprit allergen sources in polysensitized patients that facilitate the accurate prescription of AIT.6,112 One may also consider the use of recombinant allergen mixes instead of natural allergen extracts. It is also possible that the knowledge gained from molecular allergen characterization may help to improve the quality of natural allergen extracts. The disadvantages of allergen extracts are mainly related to the fact that it is technically almost impossible to manufacture them in a way to satisfy the current requirements for medicinal products due to the limitations set by raw materials, extraction, and processing (Table I) .
Recombinant allergens that exactly resemble the allergenic activity of the natural allergens as well as recombinant allergen derivatives with favorable properties for AIT are available now for decades and can be produced by controlled expression in appropriate host cells (eg, bacteria, eukaryotic cells) under defined conditions of GMP, which is the standard for medicinal products. Of course, the production of recombinant allergens and allergen derivatives requires a different know-how as compared with allergen extracts, but it is completely independent from natural and thus variable raw materials.7 Because recombinant allergenebased products are new kids on the block, they will require clinical studies and market authorizations, but ultimately such studies also need to be performed for allergen extracts; otherwise they may disappear.44 As a concrete example for the replacement of allergen extracts by recombinant allergenebased technologies, we would like to refer to grass pollen that is one of the most important allergen sources worldwide. It has been demonstrated that natural grass pollen allergen extracts show large variations regarding the contents of the individual allergens and therefore are highly heterogeneous.50 Likewise, grass pollen extractespecific AIT induces only partial protective immune responses against the individual major allergens.113,114 All these problems could be overcome with a recombinant hybrid allergen comprising the 4 major timothy grass pollen allergens: Phl p 1, Phl p 2, Phl p 5, and Phl p 6.115 This hybrid molecule can be easily produced in Escherichia coli in defined, reproducible quality and in a very large amount. The hybrid resembles the allergenic activity of grass pollen and can be used for in vivo diagnosis of grass pollen allergy. 116 The single recombinant hybrid molecule could also be used to formulate AIT vaccines for grass pollen because AIT with Phl p 1, Phl p 2, Phl p 5, and Phl p 6 has been shown to be clinically effective.25 Moreover, several AIT approaches based on recombinant hypoallergenic molecules, recombinant allergens, and allergen-derived synthetic peptides have reached clinical application in controlled studies (Table III) . One of these approaches is that a new recombinant B-cell epitope-based grass pollen allergy vaccine, termed BM32,30,31,130,131 which contains recombinant hypoallergenic fusion proteins consisting of nonallergen peptides from the 4 timothy grass pollen allergens fused to the hepatitis Bderived PreS protein as a carrier, has been shown to be hypoallergenic in vivo. 132 In AIT trials, BM32 was safe and few injections were effective in reducing symptoms of grass pollen allergy (Table III) .30,31,133,134 Thus grass pollen allergy is a very good and concrete example of how traditional allergen extracts used for in vivo testing and AIT can be replaced by modern recombinant technology.
Interestingly, recombinant allergenebased approaches seem to be not only applicable for the development of AIT approaches for respiratory allergies, but also for food and venom allergy. Regarding food allergy, a recombinant hypoallergenic mutant of the major fish allergen parvalbumin, mCyp c 1, has been expressed in E. coli and was shown to have strongly reduced allergenic activity in skin prick tests.109,135,136 The recombinant mCyp c 1 molecule was then formulated for subcutaneous AIT, and first clinical studies showed that treatment was safe and induced allergen-specific blocking IgG antibodies (ClinicalTrials.gov Identifiers: NCT02017626, NCT02365168, NCT02382718). Likewise, recombinant allergenebased strategies might be developed for venom allergy because the clinically relevant bee and wasp allergens have been expressed as recombinant proteins and could be used to develop recombinant AIT approaches.137,138
Summary
Recombinant hypoallergenic allergen derivatives comprising some of the most important allergen sources (eg, grass pollen, birch pollen, ragweed pollen, olive pollen, Parietaria pollen, cedar pollen, house dust mites, cat, dog, bee, and wasp venoms) have been characterized at a preclinical level and could be evaluated in clinical trials.130,131,139-155 For a few allergen sources, it may be challenging to prepare all the individual allergen molecules by recombinant technology to represent the complexity of the allergen source properly. However, so far recombinant AIT approaches have not reached wide-scale use in clinical practice. Because the molecules can be produced well in different expression systems, there are, in principle, no technical hurdles for their manufacturing. Some of the molecules are protected by international patents, but these are available for licensing. It rather seems that pharmaceutical companies were so far not willing to invest in their development because this would require the setting up of suitable production facilities and the conductance of clinical trials. With the implementation of regulations requesting the documentation of traditional allergen extracts by clinical trials during the last few years, the situation may change because the pharmaceutical industry is now requested to conduct GMP production and clinical trials to maintain their traditional allergen extracts on the market and/or may decide to develop recombinant allergenebased products. It is therefore likely that the pressure by the regulatory agencies will boost the development of high-quality allergens for in vivo use, and, accordingly, we may see the parallel development of allergen extract and recombinant allergenebased products for clinical use. Unfortunately, most of the current allergen extracts do not meet the criteria of medicinal products and are therefore at risk of disappearing. Even with the most advanced analytical methods, it is not possible to overcome all the quality problems that are due to the limits of allergen extractebased technologies. However, during the last 30 years, the most important allergen molecules from the most relevant allergen sources have been produced as defined recombinant molecules resembling the allergenic activity of the natural allergens. The recombinant allergen molecules can be produced at low costs, in consistent quality, and in large amounts for in vivo allergy testing and thus would meet easily the criteria set for medicinal products.
Likewise, they could be used to formulate modern allergy vaccines. Moreover, recombinant hypoallergenic allergen derivatives have been produced for most of the important allergen sources and hold promise to improve safety, efficacy, and convenience of allergen-specific immunotherapy as well as to be useful for preventive allergy vaccination. It is thus argued that the time has come to implement recombinant technology for the production of new high-quality in vivo allergy tests and allergy vaccines.
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